Breaking Finance News

Goldman Sachs Group, Inc. (The) upgraded ICON PLC (NASDAQ:ICLR) to Conviction-Buy in a report released today.

Just yesterday ICON PLC (NASDAQ:ICLR) traded -0.61% lower at $96.48. ICON PLC’s 50-day moving average is $100.50 and its 200-day moving average is $89.05. The last stock price is up 13.87% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.05% over the same time period. 233,718 shares of ICLR traded hands, down from an average trading volume of 344,973

Goldman Sachs Group, Inc. (The) has upgraded ICON PLC (NASDAQ:ICLR) to Conviction-Buy in a report released on 07/07/2017.

Recent Performance Chart


ICON PLC has 52 week low of $73.76 and a 52 week high of $109.32 with a PE ratio of 20.57 and has a market capitalization of $0.

In addition to Goldman Sachs Group, Inc. (The) reporting its stock price target, a total of 11 brokerages have issued a ratings update on ICON PLC. The 12-month price target is $77.36 with three brokers rating the stock a strong buy, 4 brokers rating the stock a buy, 7 brokerages rating the stock a hold, 0 firms rating the stock a underperform, and finally 2 firms rating the stock a sell.


ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.